| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TMIGD2 |
| Uniprot No | Q96BF3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-150aa |
| 氨基酸序列 | LSVQQGPNLLQVRQGSQATLVCQVDQATAWERLRVKWTKDGAILCQPYIT NGSLSLGVCGPQGRLSWQAPSHLTLQLDPVSLNHSGAYVCWAAVEIPELE EAEGNITRLFVDPDDPTQNRNRIASFPG |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TMIGD2重组蛋白的示例参考文献(注：以下内容为假设性示例，实际文献需通过学术数据库验证)：
---
1. **文献名称**：*TMIGD2 as a novel immune checkpoint molecule: Recombinant protein characterization and functional analysis*
**作者**：Zhang Y, Chen L, Wang X
**摘要**：本研究成功表达并纯化了TMIGD2重组蛋白，发现其通过与T细胞表面受体结合抑制T细胞活化和增殖，提示TMIGD2可能作为新型免疫检查点分子，为癌症免疫治疗提供潜在靶点。
---
2. **文献名称**：*Structural insights into TMIGD2-mediated immune regulation through recombinant protein crystallography*
**作者**：Smith J, Kumar R, Ito F
**摘要**：通过重组TMIGD2蛋白的晶体结构解析，揭示了其免疫球蛋白结构域与配体CD28H的结合模式，为设计靶向TMIGD2的免疫调节药物提供了结构基础。
---
3. **文献名称**：*Recombinant TMIGD2 protein promotes angiogenesis in tumor microenvironment via integrin signaling*
**作者**：Li H, Park S, Garcia JM
**摘要**：研究发现重组TMIGD2蛋白可通过与整合素αvβ3相互作用激活下游信号通路，促进肿瘤血管生成，提示其双重作用机制在肿瘤进展中的重要性。
---
4. **文献名称**：*Development of monoclonal antibodies against recombinant TMIGD2 for therapeutic targeting in autoimmune diseases*
**作者**：Wu T, Nguyen A, Kim D
**摘要**：利用重组TMIGD2蛋白筛选出高亲和力单克隆抗体，实验显示其在自身免疫模型中有效抑制炎症反应，验证了TMIGD2作为治疗靶点的潜力。
---
**建议**：可通过PubMed或Google Scholar搜索关键词“TMIGD2 recombinant protein”或“TMIGD2 immune function”获取最新研究。
TMIGD2 (Transmembrane and Immunoglobulin Domain-containing protein 2) is a cell surface protein belonging to the immunoglobulin superfamily (IgSF), characterized by its extracellular immunoglobulin-like domains and transmembrane region. It is primarily expressed in immune cells, including T cells, natural killer (NK) cells, and dendritic cells, where it plays roles in immune regulation and cell-cell communication. TMIGD2 has garnered interest for its dual functionality, acting as both a co-stimulatory and co-inhibitory molecule depending on cellular context and binding partners. It interacts with CD28 and HHLA2. modulating T-cell activation, proliferation, and cytokine production. Dysregulation of TMIGD2 signaling has been implicated in autoimmune diseases, cancer immune evasion, and inflammatory disorders.
Recombinant TMIGD2 protein is engineered in vitro using expression systems like mammalian cells or Escherichia coli to ensure proper folding and post-translational modifications. This protein retains the functional domains necessary for ligand binding and signaling, enabling researchers to study its interactions, structure-function relationships, and therapeutic potential. Applications include in vitro assays to dissect immune checkpoint pathways, antibody development for diagnostic or therapeutic use, and exploring its role in tumor microenvironments. Recent studies highlight TMIGD2 as a promising target for immunotherapy, particularly in cancers where HHLA2-TMIGD2 axis suppression contributes to immune resistance. However, its precise mechanisms and clinical relevance remain under investigation, necessitating further functional studies. The availability of recombinant TMIGD2 accelerates research into its biology and its exploitation for novel immunomodulatory strategies.
×
